STOCK TITAN

[8-K] LISATA THERAPEUTICS, INC. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Lisata Therapeutics furnished an investor slide presentation under Item 7.01 (Regulation FD). The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and will be used at investor and industry conferences.

The materials are expressly furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities. They are not incorporated by reference into Securities Act filings unless expressly stated.

Lisata Therapeutics ha fornito una presentazione a slide per investitori ai sensi dell'articolo 7.01 (Regulation FD). La presentazione, datata 14 ottobre 2025, è allegata come Exhibit 99.1 e sarà utilizzata a conferenze per investitori e del settore.

I materiali sono espressamente forniti, non depositati, ai sensi della Exchange Act e non sono soggetti alle responsabilità della Sezione 18. Non sono incorporati per riferimento nelle dichiarazioni presentate ai sensi della Securities Act, salvo diversa indicazione.

Lisata Therapeutics proporcionó una presentación de diapositivas para inversionistas bajo el ítem 7.01 (Regulación FD). La presentación, con fecha 14 de octubre de 2025, está adjunta como Exhibit 99.1 y se utilizará en conferencias para inversionistas y de la industria.

Los materiales se proporcionan expresamente, no se presentan/registran, bajo la Exchange Act y no están sujetos a responsabilidades de la Sección 18. No están incorporados por referencia a presentaciones de la Securities Act a menos que se indique expresamente.

Lisata Therapeutics는 Item 7.01 (Regulation FD)에 따른 투자자 슬라이드 프레젠테이션을 제공했습니다. 2025년 10월 14일자 프레젠테이션은 Exhibit 99.1로 첨부되며 투자자 및 산업 컨퍼런스에서 사용될 예정입니다.

자료는 Exchange Act에 따라 명시적으로 제공되며 제출된 것이 아니며 Section 18의 책임의 대상이 아닙니다. 명시적으로 표시되어 있지 않는 한 Securities Act 제출에 참조로 포함되지 않습니다.

Lisata Therapeutics a fourni une présentation sur diaporama destinée aux investisseurs conformément à l'article 7.01 (Réglementation FD). La présentation, datée du 14 octobre 2025, est jointe en tant que Exhibit 99.1 et sera utilisée lors de conférences pour investisseurs et dans le secteur.

Les documents sont expressément fournis, non déposés, en vertu de la Exchange Act et ne sont pas soumis aux responsabilités de l'article 18. Ils ne sont pas intégrés par référence dans les dépôts de la Securities Act, sauf indication expresse.

Lisata Therapeutics hat eine Investorenpräsentation nach Item 7.01 (Regulation FD) bereitgestellt. Die Präsentation vom 14. Oktober 2025 ist als Exhibit 99.1 beigefügt und wird auf Investoren- und Branchenkonferenzen verwendet.

Die Unterlagen werden ausdrücklich als bereitgestellt, nicht eingereicht, gemäß dem Exchange Act, und sind nicht Gegenstand von Haftungen gemäß Section 18. Sie sind nicht per Referenz in Securities-Act-Einreichungen aufgenommen, es sei denn, ausdrücklich angegeben.

Lisata Therapeutics قد قدمت عرض شرائح للمستثمرين بموجب البند 7.01 (Regulation FD). العرض، المؤرخ 14 أكتوبر 2025، مرفق كمعروض 99.1 وسيُستخدم في مؤتمرات للمستثمرين والصناعة.

المواد مُقدمة صراحة، وليست مُودعة، بموجب قانون البورصة وليست خاضعة لالتزامات القسم 18. كما أنها ليست مدمجة بالإشارة في ملفات Securities Act ما لم يُذكر صراحة.

Lisata Therapeutics 已按第7.01条(Regulation FD)向投资者提供了一份幻灯片演示文稿。该演示文稿日期为2025年10月14日,作为 Exhibit 99.1 附件,将在投资者和行业会议上使用。

材料是按照美国证券法的披露规定明确“供披露”(furnished),而非“ filed”(备案),因此不受第18条的责任约束。除非明确说明,否则不通过参照方式纳入证券法提案的文件。

Positive
  • None.
Negative
  • None.

Lisata Therapeutics ha fornito una presentazione a slide per investitori ai sensi dell'articolo 7.01 (Regulation FD). La presentazione, datata 14 ottobre 2025, è allegata come Exhibit 99.1 e sarà utilizzata a conferenze per investitori e del settore.

I materiali sono espressamente forniti, non depositati, ai sensi della Exchange Act e non sono soggetti alle responsabilità della Sezione 18. Non sono incorporati per riferimento nelle dichiarazioni presentate ai sensi della Securities Act, salvo diversa indicazione.

Lisata Therapeutics proporcionó una presentación de diapositivas para inversionistas bajo el ítem 7.01 (Regulación FD). La presentación, con fecha 14 de octubre de 2025, está adjunta como Exhibit 99.1 y se utilizará en conferencias para inversionistas y de la industria.

Los materiales se proporcionan expresamente, no se presentan/registran, bajo la Exchange Act y no están sujetos a responsabilidades de la Sección 18. No están incorporados por referencia a presentaciones de la Securities Act a menos que se indique expresamente.

Lisata Therapeutics는 Item 7.01 (Regulation FD)에 따른 투자자 슬라이드 프레젠테이션을 제공했습니다. 2025년 10월 14일자 프레젠테이션은 Exhibit 99.1로 첨부되며 투자자 및 산업 컨퍼런스에서 사용될 예정입니다.

자료는 Exchange Act에 따라 명시적으로 제공되며 제출된 것이 아니며 Section 18의 책임의 대상이 아닙니다. 명시적으로 표시되어 있지 않는 한 Securities Act 제출에 참조로 포함되지 않습니다.

Lisata Therapeutics a fourni une présentation sur diaporama destinée aux investisseurs conformément à l'article 7.01 (Réglementation FD). La présentation, datée du 14 octobre 2025, est jointe en tant que Exhibit 99.1 et sera utilisée lors de conférences pour investisseurs et dans le secteur.

Les documents sont expressément fournis, non déposés, en vertu de la Exchange Act et ne sont pas soumis aux responsabilités de l'article 18. Ils ne sont pas intégrés par référence dans les dépôts de la Securities Act, sauf indication expresse.

Lisata Therapeutics hat eine Investorenpräsentation nach Item 7.01 (Regulation FD) bereitgestellt. Die Präsentation vom 14. Oktober 2025 ist als Exhibit 99.1 beigefügt und wird auf Investoren- und Branchenkonferenzen verwendet.

Die Unterlagen werden ausdrücklich als bereitgestellt, nicht eingereicht, gemäß dem Exchange Act, und sind nicht Gegenstand von Haftungen gemäß Section 18. Sie sind nicht per Referenz in Securities-Act-Einreichungen aufgenommen, es sei denn, ausdrücklich angegeben.

0000320017false00003200172025-10-142025-10-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

October 14, 2025
Date of Report (date of earliest event reported)

LISATA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-33650
22-2343568
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
110 Allen Road, Second Floor, Basking Ridge, NJ 07920
(Address of Principal Executive Offices)(ZipCode)
(908) 842-0100
Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareLSTA
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 7.01 Regulation FD Disclosure.

On October 14, 2025, Lisata Therapeutics, Inc. (the "Company") issued a slide presentation that the Company will use at investor and industry conferences and presentations. A copy of this presentation is attached to this Current Report as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. 

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statement and Exhibits.
Exhibit No.Description
99.1
Lisata Therapeutics, Inc. Corporate Presentation, October 14, 2025


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



LISATA THERAPEUTICS, INC.

By: /s/ David J. Mazzo            
Name: David J. Mazzo, PhD
Title: President & Chief Executive Officer
Dated: October 14, 2025

FAQ

What did LSTA announce in this 8-K?

The company furnished an investor slide presentation under Item 7.01 (Regulation FD), attached as Exhibit 99.1.

When is the Lisata investor presentation dated?

The presentation is dated October 14, 2025.

Is the information considered filed or furnished?

It is furnished and not deemed filed, and therefore not subject to Section 18 liabilities.

Will the presentation be used publicly?

Yes. Lisata plans to use it at investor and industry conferences and presentations.

Is Exhibit 99.1 incorporated by reference into other filings?

No, not unless expressly stated in a future filing.

What is the exhibit number and description?

Exhibit 99.1: Lisata Therapeutics, Inc. Corporate Presentation, October 14, 2025.
Lisata Therapeutics Inc

NASDAQ:LSTA

LSTA Rankings

LSTA Latest News

LSTA Latest SEC Filings

LSTA Stock Data

21.19M
7.02M
19.82%
8.94%
0.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
BASKING RIDGE